XNYS · Diagnostics & Research
Last stored close · Sep 18, 2026
Close · Sep 18, 2026
$651.45-1.04%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
53/100
Moderate
Score components
TickerWhale View
Thermo Fisher Scientific scores 53 out of 100 overall, which we rate moderate. Technical is its strongest area and Valuation its weakest.
What helps
- Technical
- Sentiment Signal
What to watch
- Quality & growth
- Valuation
- Risk
Quality & growth
30%40Weak
- Revenue growth 7.2%
- EPS growth 7.4%
Valuation
25%23Weak
- P/E 34.7
- EV/Sales 6.0
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
#51 by market cap in our coverage · ~125,000 employees · Listed 1972-06-01 · www.thermofisher.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#82 / 139sector rank by TickerWhale Score
TickerWhale Score 53 vs sector average 55.1 (-2.1)
Revenue growth (industry)Top 63%
Gross margin (industry)Top 71%
Return on equity (industry)Top 53%
P/E (industry)Cheaper than 50%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
99/100Strong vs universe
Ranks 99th of 100 covered names on our technical composite — the composite itself scores 84/100 · 25% of the TickerWhale Score
Classic chart indicators
Buy
5 buy · 2 sell · 1 neutral of 8 votes
TickerWhale rates TMO's technical setup strong — 99th percentile of the covered universe. Classic chart indicators lean buy, pointing the same way.
Moving averages
9 / 9constructive
- vs 200-day+21.1%
- vs 50-day+10.2%
Momentum
Mixed
- RSI (14)68 · neutral
- Stochasticsell
- CCIbuy
- Williams %Rsell
Trend
Constructive
- ADX (14) trend strength28· trending
- MACD (12,26,9)buy(histogram 2.411)
How the classic verdict is reached
Moving averages (9) agree on buy — 9 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 4 buy · 2 sell · 1 neutral.
Result — 5 buy vs 2 sell of 8 votes = Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-09-18 · revised_latestValuation multiples
- P/E (TTM)34.7
- P/S (TTM)5.2
- P/B4.6
- EV/EBITDA—
- EV/Sales6.0
- PEG4.69
Profitability & returns
- Gross margin40.8%
- Net margin15.0%
- ROE13.3%
- Debt/Equity0.81
Growth
- Revenue growth (YoY)7.2%
- EPS growth (YoY)7.4%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $241.7B
Fundamentals history
Reported statement totals across recent periods.
| Metric | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | $44.6B | $42.9B | $42.9B |
| Gross profit | $18.2B | $17.7B | $17.1B |
| Operating income | $7.7B | $7.3B | $6.9B |
| Net income | $6.7B | $6.3B | $6.0B |
| EPS (diluted) | $17.74 | $16.53 | $15.45 |
| Free cash flow | $6.3B | $7.3B | $7.0B |
| Cash | $9.9B | $4.0B | $8.1B |
| Total debt | $39.4B | $31.3B | $34.9B |
| Equity | $53.4B | $49.6B | $46.7B |
| Net debt | $29.5B | $27.3B | $26.8B |
| Debt / equity | 0.74 | 0.63 | 0.75 |
| Liabilities / assets | 0.52 | 0.49 | 0.53 |
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: MU →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TMOCurrentThermo Fisher Scientific | 53 | 84 | 34.7 | — | 4.6 | 6.0 | $651.45 | -1.04% | +7.2% | ||
| EXELExelixis | 81 | 80 | 17.6 | — | 8.2 | 6.1 | $58.36 | -0.22% | +9.2% | ||
| INCYIncyte | 81 | 76 | 16.2 | — | 4.1 | 3.8 | $125.31 | -1.81% | +26.9% | ||
| ACADAcadia Pharmaceuticals | 80 | 63 | 12.4 | — | 3.6 | 3.8 | $27.29 | -0.58% | +11.8% | ||
| OSCROscar Health Inc - | 78 | 67 | 19.5 | — | 5.2 | 0.5 | $32.13 | +0.47% | +43.1% | ||
| TGTXTG Therapeutics | 77 | 73 | 20.3 | — | 14.8 | 11.5 | $56.87 | +0.71% | +76.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.